Inhaled corticosteroids and COVID-19 outcomes in asthma: the Israeli experience

To the Editor:

Inhaled corticosteroids (ICS), alone or in combination with bronchodilators, are widely used in asthma [1]. ICS have potential immunosuppressive effects that may promote viral replication, delayed viral clearance and increased risks of secondary infections [2, 3]. Furthermore, ICS use in asthma is associated with an increased risk of upper respiratory tract infections [2, 3]. Therefore, in the face of the current coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, concerns have been raised whether the use of ICS in asthmatic patients increases the risk of SARS-CoV-2 infection and affects COVID-19 severity and mortality.

In the current study, we examined two objectives: 1) the association between ICS use and SARS-CoV-2 infection in asthmatic patients, using a test negative case–control study approach; and 2) the association between ICS use in asthmatic patients with PCR positivity for SARS-CoV-2 and COVID-19 severity and mortality, using a retrospective cohort study approach.

The study was approved by the Clalit Health Services (CHS) institutional review board and was exempt from the requirement for informed consent.

We used the computerised database of CHS to retrospectively identify all ≥18-year-olds with an asthma diagnosis (International Classification of Diseases, ninth revision: 493.xx) who had seen at least twice by a pulmonologist in the past 5 years and underwent PCR testing for SARS-CoV-2 between 1 March 2020 and 17 December 2020. All identified patients who underwent PCR testing for SARS-CoV-2 served to assess the association between ICS use and SARS-CoV-2 infection, using a test negative case–control study approach. In this approach, positive PCR patients constituted the cases and negative PCR patients constituted the control group. Asthmatic patients with positive PCR for SARS-CoV-2 served to assess the association between ICS use and moderate–severe COVID-19 and with composite of moderate–severe COVID-19 and 90-days all-cause mortality, using a retrospective cohort study approach. COVID-19 severity was defined according to the Israeli Ministry of Health’s guidelines, which are in accordance with the World Health Organization definitions [4].

ICS use was determined using the CHS pharmacy records using the Anatomical Therapeutic Chemical classification codes. Based on the timing of ICS prescriptions filled in the previous year, patients were classified into three categories: none versus recent (≤90 days) versus former (90–365 days).

Logistic regression models were used to examine the association between ICS and PCR positivity, and Cox proportional hazard regression models were used to assess the association between ICS use and COVID-19 severity. Multivariable models were adjusted for age, sex, ethnicity, diabetes, hypertension, ischaemic heart disease, obesity, hospitalisation in the prior year and systemic corticosteroid use.

A total of 10,242 asthmatics (age ≥18 years) underwent PCR testing for SARS-CoV-2 between 1 March 2020 and 17 December 2020. Of them, 6,688 (65.3%) patients used ICS in the year prior to the PCR test. Overall, 996 (9.42%) patients were found to be positive for SARS-CoV-2. With regard to the first study objective, no significant association was found between ICS use and SARS-CoV-2 infection; compared to nonusers, the adjusted odds ratios were 1.06 (95% CI 0.91–1.23) for recent ICS users and 0.93 (95% CI 0.83–1.04) for former ICS users.

Cite this article as: Adir Y, Fireman Klein E, Saliba W. Inhaled corticosteroids and COVID-19 outcomes in asthma: the Israeli experience. ERJ Open Res 2022; 8: 00014-2022 [DOI: 10.1183/23120541.00014-2022].
Recent studies suggest that ICS suppress SARS-CoV-2 replication and reduce the expression in bronchial epithelial cells of angiotensin-converting enzyme 2 receptor, which mediates SARS-CoV-2 cell entry [5–8]. Further, the available data from most of the epidemiological studies generally suggest that ICS are not an independent risk factor for increased SARS-CoV-2 infectivity or COVID-19 severity, advising that ICS treatment in patients with asthma is safe and should be continued during the COVID-19 pandemic [9–13]. However, other studies reported some conflicting results, such the study by SCHULTZE et al. [14] that by using the OpenSAFELY platform, reported an increased risk of death from COVID-19 among people with asthma on high-dose ICS. Although various sensitivity analyses indicated that this increased mortality risk could be explained by unmeasured confounders, including disease severity and risk factors for severe COVID-19, the question whether regular ICS therapy for asthma is safe in the current SARS-CoV-2 pandemic is still not completely answered. The results of our study suggest that, in asthmatic patients, recent and former use of ICS are not associated with increased risk of SARS-CoV-2 infection nor with increased risk of COVID-19 severity or mortality.

The limitations of the study include lack of data about asthma severity, and limitations related to the observational and retrospective nature of the study.

In summary, our study adds to the strength of the current evidence and the current recommendation that the use of ICS is safe, and asthmatic patients should continue to take their prescribed asthma medication as usual, including ICS alone or in combination with a long-acting β2-agonist, during the COVID-19 pandemic.

Yochai Adir1,2, Einat Fireman Klein o1,2 and Walid Saliba2,3

1Pulmonary Division, Lady Davis Carmel Medical Center, Faculty of Medicine Technion Institute of Technology, Haifa, Israel. 2Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

**TABLE 1**

| Variables                        | Association of ICS use with SARS-CoV-2 infection OR (95% CI), p-value | Association of ICS use with COVID-19 severity and mortality | Moderate–severe COVID-19 HR (95% CI), p-value | Composite of moderate–severe COVID-19 and all-cause mortality HR (95% CI), p-value |
|----------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------|---------------------------------------------|-----------------------------------------------------------------------------------|
| Age                              | 1.00 (0.99–1.00), 0.799                                                |                                                              | 1.03 (1.02–1.05), <0.001                    | 1.04 (1.02–1.05), <0.001                                                        |
| Female sex                       | 0.92 (0.80–1.06), 0.270                                                |                                                              | 0.64 (0.41–1.00), 0.050                     | 0.67 (0.44–1.04), 0.073                                                         |
| Arab ethnicity                   | 2.44 (2.09–2.86), <0.001                                               |                                                              | 2.00 (1.28–3.14), 0.003                     | 1.85 (1.20–2.86), 0.006                                                         |
| Diabetes                         | 1.18 (0.97–1.44), 0.093                                                |                                                              | 0.80 (0.49–1.29), 0.352                     | 0.79 (0.50–1.26), 0.320                                                         |
| Hypertension                     | 0.99 (0.82–1.21), 0.940                                                |                                                              | 2.02 (1.17–3.51), 0.012                     | 2.05 (1.21–3.50), 0.008                                                         |
| Obesity                          | 1.21 (1.04–1.40), 0.013                                                |                                                              | 1.75 (1.10–2.78), 0.019                     | 1.68 (1.08–2.61), 0.021                                                         |
| Ischaemic heart disease          | 0.99 (0.77–1.27), 0.928                                                |                                                              | 0.92 (0.53–1.58), 0.758                     | 0.99 (0.59–1.66), 0.981                                                         |
| Hospitalisation in the prior year| 0.86 (0.73–1.02), 0.79                                                |                                                              | 1.86 (0.88–3.92), 0.104                     | 1.80 (0.89–3.64), 0.102                                                         |
| Recent systemic corticosteroid use | 0.89 (0.72–1.10), 0.279                                              |                                                              | 1.54 (0.93–2.52), 0.090                     | 1.41 (0.86–2.30), 0.172                                                         |

Recent vs. non-ICS use.

Multivariable models were adjusted for age, sex, ethnicity, diabetes, hypertension, ischaemic heart disease, obesity, hospitalisation in the prior year and systemic corticosteroid use. #: compared to Jewish ethnicity; ¶: ⩽90 days; +: 90–365 days.
Technology, Haifa, Israel. Dept of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Haifa, Israel.

Corresponding author: Yochai Adir (adir-sh@zahav.net.il)

Provenance: Submitted article, peer reviewed.

Conflict of interest: Y. Adir reports personal fees from Teva, grants and personal fees from GSK and AstraZeneca, and personal fees from Sanofi, BI and Kamada, outside the submitted work. E. Fireman Klein has nothing to disclose. W. Saliba has nothing to disclose.

References
1. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2020. www.ginasthma.org
2. Singanayagam A, Glenville N, Girkin JL, et al. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. Nat Commun 2018; 9: 2229.
3. Yang M, Zhang Y, Chen H, et al. Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma: a meta-analysis. Infection 2019; 47: 377–385.
4. World Health Organization. Clinical management of COVID-19 World Health Organization. www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=EAIaIQobChMIo_XM_pik6wIlVyrHTCh2-NAL6AAYASAEgKZRD_BwE. Date last updated: 2020. Date last accessed: August 17, 2020.
5. Yamaya M, Nishimura H, Deng X. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig 2020; 58: 155–168.
6. Matsuyama S, Kawase M, Nao N, et al. The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication–transcription complex in cultured cells. J Virol 2020; 95: e01648-20.
7. Finney LJ, Glenville N, Farne H, et al. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon. J Allergy Clin Immunol 2021; 147: 510–519.
8. Peters MC, Sajuthi S, Deford P, et al. COVID-19 related genes in sputum cells in asthma: relationship to demographic features and corticosteroids. Am J Respir Crit Care Med 2020; 202: 83–90.
9. Terry PD, Heidel RE, Dhand R. Asthma in adult patients with COVID-19: prevalence and risk of severe disease. Am J Respir Crit Care Med 2021; 203: 893–905.
10. Lovinsky-Desir S, Deshpande DR, De A, et al. Asthma among hospitalized patients with COVID-19 and related outcomes. J Allergy Clin Immunol 2020; 146: 1027–1034.
11. Chhiba KD, Patel GB, Vu THT, et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol 2020; 146: 307–314.
12. Bloom CI, Drake TM, Docherty AB, et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med 2021; 9: 699–711.
13. Sen P, Majumdar U, Zein J, et al. Inhaled corticosteroids do not adversely impact outcomes in COVID-19 positive patients with COPD: an analysis of Cleveland Clinic’s COVID-19 registry. PLoS ONE 2021; 16: e0252576.
14. Schultze A, Walker AJ, MacKenna B, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med 2020; 8: 1106–1120.